The Veteran's prostate disorder, including residuals of prostate cancer and benign prostatic hypertrophy, is not service connected as due to exposure to herbicides or secondary to his service-connected bladder cancer.
The deciding factor: The VA examiner found that the Veteran's current prostate disorder less likely than not originated during his active duty service, as a result of any incident including his exposure to Agent Orange, or as secondary to his service-connected bladder cancer, or aggravated by his bladder cancer. The examiner stated that hypertrophy of the prostate is not caused by or aggravated by bladder cancer and is etiologically unrelated to service or bladder cancer.
- Claimed conditions
- Prostate disorder, Residuals of prostate cancer, Benign prostatic hypertrophy
- How they argued it
- Secondary to another service-connected condition
- Exposure basis
- None
- Rating
- Not verified here — check the original decision
- Decision date
- May 28, 2013
- Citation
- 1317400
This is a plain-language summary generated by AI from a public Board of Veterans’ Appeals decision. It can contain errors — always verify against the original. Read the original VA decision (opens in a new tab) using citation 1317400.
What this means for you
A final Board denial may be appealed to the U.S. Court of Appeals for Veterans Claims, generally within 120 days of the Board mailing date. A Supplemental Claim with new and relevant evidence is a separate option. Another Higher-Level Review of the Board decision is not available. Check your own notice: this historical decision does not set your deadline.
What you can do next
Use your own notice and decision stage. A remanded issue is not a final court-appealable denial. VA review guidance and CAVC filing instructions (U.S. federal; reviewed October 7, 2026).
Related decisions
Other Board decisions on a similar condition or argued the same way.
- Whole decision: Denied
The Board denied service connection for bladder and prostate disorders, finding that the evidence does not support a link to service or environmental exposures. The Veteran's claims were based on direct causation rather than presumptive exposure.
- Whole decision: Remanded (sent back)
The Board remands the claims for a rating reduction and increased rating for prostate cancer, as well as the TDIU claim, due to the need for additional development of evidence.
- Whole decision: Denied
The Board denied an earlier effective date for service connection of residuals of prostate cancer, finding that the August 10, 2022 effective date is appropriate under the PACT Act.
- Whole decision: Denied
The Board denied service connection for residuals of testicular, prostate, and lung cancer as the conditions were not incurred during a period of ACDUTRA and are not related to any in-service injury or disease.
Free starter guide for your own claim
Reading this because you were denied or under-rated? Get the plain-English next steps — your appeal options, the deadline that protects you, and how appeals like yours turn out. One email, no spam.
We will only use this to send the guide. No spam, unsubscribe any time. We never sell your information.
We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.
This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.